Variants in the leucine-rich repeat kinase 2 (
LRRK2; OMIM 609007) and glucocerebrosidase (
GBA; OMIM 606463) genes are frequent and worldwide genetic contributors to Parkinson disease (PD) susceptibility.
1,2
LRRK2 variations occur in approximately 2% of PD overall, and up to 40% of PD in certain ethnic groups, particularly individuals of Ashkenazi Jewish or Arabian Berber descent.
1
GBA variation and risk variants in
GBA may be present in as many of 10% of PD worldwide and in approximately 15% or greater in PD among individuals of Ashkenazi Jewish descent.
2-4 Wide ranges in conferred disease risk exist based on allelic heterogeneity. The penetrance of
LRRK2 variations (specifically G2019S), or the chance that a carrier of this variation will manifest PD by late adulthood, has been estimated at 26% to 43% and is lower in individuals with
GBA variations, ranging from 9% to 19%.
5-8 Therefore, additional risk factors are clearly at play.
9-11 One potential critical interaction is the association of
GBA and
LRRK2 variations in carriers of both variations (hereafter, LRRKR2/GBA).